Company Description

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing.

Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs.

The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.

Salarius Pharmaceuticals, Inc. is based in Houston, Texas.

Salarius Pharmaceuticals, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Frederick Pierce

Contact Details

Address: 2450 Holcombe Blvd., Suite X Houston, Texas 77021 United States
Phone	713 913 5608
Website	salariuspharma.com

Stock Details

Ticker Symbol	SLRX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1615219
CUSIP Number	79400X503
ISIN Number	US79400X5032
Employer ID	46-5087339
SIC Code	2834

Key Executives

Name	Position
Frederick E. Pierce II	Chief Executive Officer
Jodi Cooper M.S.	Director of Operations
Dr. Michael M. Lipp Ph.D.	Chief Technology Officer
Barb Hibner Ph.D.	Chief Scientific Officer
Dr. Shahin Gharakhanian DPH, M.D.	Chairman of the Scientific Advisory Board and Acting Chief Medical Officer
Peter K. Marschel M.B.A., M.S.	Chief Business Officer

Latest SEC Filings

Date	Type	Title
Nov 19, 2025	8-K	Current Report
Nov 18, 2025	SCHEDULE 13G	Filing
Nov 17, 2025	8-K	Current Report
Nov 14, 2025	10-Q	Quarterly Report
Nov 14, 2025	SCHEDULE 13G	Filing
Nov 13, 2025	8-K	Current Report
Nov 12, 2025	424B4	Prospectus
Nov 10, 2025	FWP	Free Writing Prospectus
Nov 7, 2025	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 7, 2025	DEF 14A	Other definitive proxy statements

View All SEC Filings